SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Genetown
Biogen Sinks Some More After Doctors Fear More Brain Infections Will Occur in Patients Taking Drugs Like Tecfidera
August 7, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Watch Out Gilead, Investors Feel Vertex May Be Biogen’s Good Fit
July 31, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Four Boston Biotechs That Could Make M&A Moves This Year
July 30, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Biogen Chairman Reassures Investors With $3 Million Stock Buy
July 29, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Allergan Could Set its Sights on Another Transformative M&A Deal With Biogen, Amgen or AbbVie
July 28, 2015
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Takeover Target or Potential Buyer? Analysts Speculate on Biogen’s Future After Big Stock Drop
July 28, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Biogen and Eli Lilly’s Alzheimer’s Drugs Hint At Promise, But Fail To Dazzle
July 22, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Excited Over Eli Lilly and Biogen’s Upcoming Alzheimer’s Drug Data
July 20, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Genetown
Biogen Reports Second Non-Fatal Tecfidera PML Case
July 17, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More